GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jeil Pharma Holdings Inc (XKRX:002620) » Definitions » Capex-to-Revenue

Jeil Pharma Holdings (XKRX:002620) Capex-to-Revenue : 0.01 (As of Mar. 2024)


View and export this data going back to 1988. Start your Free Trial

What is Jeil Pharma Holdings Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Jeil Pharma Holdings's Capital Expenditure for the three months ended in Mar. 2024 was ₩-1,926.35 Mil. Its Revenue for the three months ended in Mar. 2024 was ₩188,831.48 Mil.

Hence, Jeil Pharma Holdings's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.01.


Jeil Pharma Holdings Capex-to-Revenue Historical Data

The historical data trend for Jeil Pharma Holdings's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jeil Pharma Holdings Capex-to-Revenue Chart

Jeil Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.03 0.03 0.01

Jeil Pharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.01 0.01 0.01

Competitive Comparison of Jeil Pharma Holdings's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Jeil Pharma Holdings's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jeil Pharma Holdings's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jeil Pharma Holdings's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Jeil Pharma Holdings's Capex-to-Revenue falls into.



Jeil Pharma Holdings Capex-to-Revenue Calculation

Jeil Pharma Holdings's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-9836.628) / 804043.002
=0.01

Jeil Pharma Holdings's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1926.35) / 188831.48
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jeil Pharma Holdings  (XKRX:002620) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Jeil Pharma Holdings Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Jeil Pharma Holdings's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Jeil Pharma Holdings (XKRX:002620) Business Description

Traded in Other Exchanges
N/A
Address
745-5, Banpo-dong, Seocho-gu, Seoul, KOR, 137-810
Jeil Pharma Holdings Inc is involved in manufacture and distribution of pharmaceutical products. The company mainly produces finished pharmaceutical products and active pharmaceutical ingredients. It has categorized its products in Antibiotic, Oncology, Cardiovascular, Gastrointestinal, Urology, Respiratory etc. The firm's manufacturing facility and research and development institute located at Yongin-si, Gyeonggi-do in Korea.

Jeil Pharma Holdings (XKRX:002620) Headlines

No Headlines